Agilent Technologies Inc. (A)
NYSE: A
· Real-Time Price · USD
109.74
0.83 (0.76%)
At close: May 22, 2025, 3:59 PM
109.06
-0.62%
Pre-market: May 23, 2025, 04:00 AM EDT
Agilent Revenue Breakdown
| Period Ending | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 | Oct 31, 2020 | Oct 31, 2019 | Oct 31, 2018 | Oct 31, 2017 | Oct 31, 2016 | Oct 31, 2015 | Oct 31, 2014 | Oct 31, 2013 | Oct 31, 2012 | Oct 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab Revenue | 1.64B | 1.57B | 1.45B | 2.2B | 1.9B | 1.84B | 1.7B | 1.53B | 1.42B | 662M | 2.37B | 2.3B | 402M | 1.79B |
| Agilent CrossLab Revenue Growth | +4.85% | +7.99% | -34.00% | +15.79% | +3.26% | +8.17% | +11.10% | +7.82% | +114.50% | -72.09% | +3.13% | +472.14% | -77.57% | n/a |
| Diagnostics and Genomics Revenue | 1.65B | 1.41B | 1.39B | 1.3B | 1.05B | 1.02B | 943M | 772M | 709M | n/a | n/a | n/a | 1.58B | n/a |
| Diagnostics and Genomics Revenue Growth | +17.18% | +1.44% | +7.18% | +23.78% | +2.55% | +8.27% | +22.15% | +8.89% | n/a | n/a | n/a | n/a | n/a | n/a |
| Life Sciences and Applied Markets Revenue | 3.21B | 3.86B | 4.01B | 2.82B | 2.39B | 2.3B | 2.27B | 2.17B | 2.07B | n/a | n/a | n/a | n/a | n/a |
| Life Sciences and Applied Markets Revenue Growth | -16.62% | -3.77% | +41.94% | +18.02% | +3.91% | +1.41% | +4.66% | +4.63% | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 | Jul 31, 2019 | Apr 30, 2019 | Jan 31, 2019 | Oct 31, 2018 | Jul 31, 2018 | Apr 30, 2018 | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 | Jan 31, 2017 | Oct 31, 2016 | Jul 31, 2016 | Apr 30, 2016 | Jan 31, 2016 | Oct 31, 2015 | Jul 31, 2015 | Apr 30, 2015 | Jan 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 410M | 397M | 395M | 380M | 393M | 393M | 407M | 415M | 419M | 422M | 412M | 386M | 417M | 389M | 403M | 420M | 407M | 387M | 347M | 358M | 404M | 385M | 366M | 354M | 355M | 356M | 339M | 338M | 341M | 325M | 308M | 307M | 289M | 321M | 310M | 318M | 304M | 297M | 290M | 292M | 310M |
| Selling, General, and Administrative Revenue Growth | +3.27% | +0.51% | +3.95% | -3.31% | 0.00% | -3.44% | -1.93% | -0.95% | -0.71% | +2.43% | +6.74% | -7.43% | +7.20% | -3.47% | -4.05% | +3.19% | +5.17% | +11.53% | -3.07% | -11.39% | +4.94% | +5.19% | +3.39% | -0.28% | -0.28% | +5.01% | +0.30% | -0.88% | +4.92% | +5.52% | +0.33% | +6.23% | -9.97% | +3.55% | -2.52% | +4.61% | +2.36% | +2.41% | -0.68% | -5.81% | n/a |
| Research and Development Revenue | 113M | 111M | 127M | 113M | 120M | 114M | 118M | 126M | 123M | 119M | 116M | 115M | 117M | 116M | 113M | 109M | 103M | 102M | 92M | 197M | 104M | 102M | 101M | 99M | 102M | 104M | 97M | 91M | 93M | 89M | 87M | 84M | 79M | 84M | 86M | 81M | 78M | 82M | 79M | 81M | 88M |
| Research and Development Revenue Growth | +1.80% | -12.60% | +12.39% | -5.83% | +5.26% | -3.39% | -6.35% | +2.44% | +3.36% | +2.59% | +0.87% | -1.71% | +0.86% | +2.65% | +3.67% | +5.83% | +0.98% | +10.87% | -53.30% | +89.42% | +1.96% | +0.99% | +2.02% | -2.94% | -1.92% | +7.22% | +6.59% | -2.15% | +4.49% | +2.30% | +3.57% | +6.33% | -5.95% | -2.33% | +6.17% | +3.85% | -4.88% | +3.80% | -2.47% | -7.95% | n/a |